NASDAQ · CRGX
Healthcare · Biotechnology
$4.47
Up+$0.00 (+0.00%)
Updated Oct 7, 2026, 12:03 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CRGX
1M range · 0 trading sessions · Daily adjusted prices
CRGX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CRGX.
Company
Market Activity
Research & News
CRGX research
Company profile and research snapshot.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2025 | Jefferies | Hold | — |
| Jan 30, 2025 | Truist Securities | Hold | — |
| Jan 30, 2025 | Piper Sandler | Neutral | — |
| Jan 30, 2025 | Chardan Capital | Neutral | — |
| Jan 30, 2025 | JP Morgan | Underweight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 8, 2025
CARGO Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire CARGO for $4.379 in cash per share, plus a contingent value right. The merger is expected to close in August 2025.
The Motley Fool · Aug 16, 2024
Cargo Therapeutics, a clinical-stage biotech company, saw its stock price rise by nearly 19% this week after reporting its Q2 earnings. The company's net loss for the quarter was less than expected, and it made progress in its Phase 2 clinical trial for its cancer drug Firi-cel CRG-022.
GlobeNewswire Inc. · Jun 4, 2024
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
GlobeNewswire Inc. · May 28, 2024
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRGX.
No results
No recent SID articles mention CRGX.
